Article ID Journal Published Year Pages File Type
6158262 American Journal of Kidney Diseases 2010 12 Pages PDF
Abstract
Using ESAs to target a hemoglobin level >12 g/dL is associated with worse clinical outcomes and significant additional cost compared with using ESAs to target lower hemoglobin levels (9-12 g/dL). Given a lack of studies comparing low (9-10.9 g/dL) and intermediate (11-12 g/dL) hemoglobin targets for clinical outcomes, including quality of life, the most cost-effective hemoglobin level target within the range of 9-12 g/dL is uncertain, although aiming for higher targets within this range will lead to higher costs.
Related Topics
Health Sciences Medicine and Dentistry Nephrology
Authors
, , , , , , , , , , ,